TomÃ¡Å¡ Å tulc

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6733931/publications.pdf

Version: 2024-02-01

29	799	840119	552369
papers	citations	11 h-index	26 g-index

35	35	35	1149
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. Journal of Clinical Investigation, 2000, 106, 1263-1270.	3.9	295
2	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology, 2016, 225, 184-196.	0.8	155
3	Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition, 2001, 17, 721-723.	1.1	57
4	Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects?. Diabetes Research and Clinical Practice, 2010, 88, 125-131.	1.1	51
5	Statin Intolerance: the Clinicianâ€™s Perspective. Current Atherosclerosis Reports, 2015, 17, 69.	2.0	43
6	Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. European Journal of Pharmacology, 2004, 493, 183-189.	1.7	35
7	Repeatability of noninvasive surrogates of endothelial function. American Journal of Cardiology, 2004, 94, 693-696.	0.7	30
8	Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. American Heart Journal, 2003, 146, 1060-1063.	1.2	26
9	Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. American Heart Journal, 2003, 146, 110A-115A.	1.2	22
10	Ivabradine in Stable Coronary Artery Disease. New England Journal of Medicine, 2014, 371, 2435-2435.	13.9	16
11	APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. Clinical Chemistry and Laboratory Medicine, 2008, 46, 773-7.	1.4	12
12	A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. Archives of Medical Science, 2017, 4, 705-710.	0.4	9
13	PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. Atherosclerosis, 2003, 166, 195-196.	0.4	8
14	Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. Atherosclerosis, 2003, 166, 197-198.	0.4	8
15	Immunocytochemical detection of estrogen receptors in bone cells using flow cytometry. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1356, 95-100.	1.9	7
16	Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. Atherosclerosis, 2005, 183, 367-368.	0.4	7
17	Statins, Glycemia, and Diabetes Mellitus: Another Point of View. Current Atherosclerosis Reports, 2014, 16, 458.	2.0	4
18	Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?. Medical Science Monitor, 2008, 14, RA45-7.	0.5	3

#	Article	IF	Citations
19	Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?. Medical Hypotheses, 2008, 70, 199-200.	0.8	2
20	IMPACT OF APOLIPOPROTEIN A5 GENE VARIANTS ON STATIN TREATMENT EFFICACY. Atherosclerosis Supplements, 2008, 9, 40.	1.2	2
21	Ivabradine, Coronary Heart Disease, and Heart Failure: Time for Reappraisal. Current Atherosclerosis Reports, 2014, 16, 463.	2.0	2
22	Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients. Nutrition Research, 2007, 27, 181-185.	1.3	1
23	PO17-487 ADEQUATELY TREATED TYPE 2 DIABETES IS ASSOCIATED WITH LOWER WALL SHEAR RATE OF THE COMMON CAROTID ARTERY. Atherosclerosis Supplements, 2007, 8, 136.	1.2	1
24	Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?. Current Pharmaceutical Design, 2015, 21, 1180-1184.	0.9	1
25	The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus. Neuroendocrinology Letters, 2012, 33 Suppl 2, 73-7.	0.2	1
26	W15-P-006 Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. Atherosclerosis Supplements, 2005, 6, 98.	1.2	0
27	We-P11:117 Rosiglitazone improves quality of lipoproteins in patients with type 2 diabetes. Atherosclerosis Supplements, 2006, 7, 371.	1.2	0
28	Is it safe to combine PPAR agonists? A lesson from muraglitazar. Medical Hypotheses, 2006, 67, 669.	0.8	0
29	PO9-212 EFFECT OF ROSIGLITAZONE ON LEUKOCYTE EXPRESSION OF PROINFLAMMATORY AND PROTHROMBOTIC MOLECULES IN PATIENTS WITH TYPE 2 DIABETES. Atherosclerosis Supplements, 2007, 8, 69.	1.2	0